MEDP Overview

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Wall Street analysts forecast MEDP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is569.17 USD with a low forecast of 462.00 USD and a high forecast of 660.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Medpace Holdings Inc revenue for the last quarter amounts to 706.60M USD, increased 26.50

Medpace Holdings Inc. EPS for the last quarter amounts to 4.28 USD, increased 16.62

Medpace Holdings Inc (MEDP) has 5900 emplpoyees as of May 10 2026.

Today MEDP has the market capitalization of 12.11B USD.